Scholarlink

<p>To characterize the economic and humanistic burden of patients with hematologic malignancies in Japan using real-world data. Patients with a claim record for a hematologic malignancy who responded to a survey regarding productivity loss and quality of life (QoL) were analyzed to assess their direct medical cost, productivity loss, and QoL along with their levels of comorbidity. This study identified a main cohort of 122 patients with a hematologic malignancy who responded to Work Productivity and Activity Impairment (WPAI) and EQ-5D-5&#xa0;L questionnaires. Median patient age was 54.5 years (range 25–71 years), with median Charlson Comorbidity Score (CCI) of 2. Most of the mean total cost (USD 12,836.14; JPY 1,670,624) was attributed to productivity loss (mean USD 8,106.39; JPY 1,055,046) rather than direct medical cost (mean USD 4,729.76; JPY 615,578). Presenteeism (mean USD 5,117.84; JPY 666,086) accounted for a greater proportion of productivity loss than absenteeism (mean USD 2,988.55; JPY 388,960). Deterioration in QoL (-0.045) was observed in comparison to the general population in Japan. The results point to the need for a social security policy to provide appropriate support such as better therapies or access for patients who must receive treatment while still working.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Unveiling economic and humanistic burden of hematologic malignancies in Japan with personal health record data

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年1月27日

查看全文
  • Saaya Tsutsué,
  • Kenshi Suzuki,
  • Sooyeol Lim,
  • Ryosuke Nishi,
  • Honoka Nakamura,
  • Hiroya Asou,
  • Anila Mathew,
  • Takunari Yoshinaga

摘要

To characterize the economic and humanistic burden of patients with hematologic malignancies in Japan using real-world data. Patients with a claim record for a hematologic malignancy who responded to a survey regarding productivity loss and quality of life (QoL) were analyzed to assess their direct medical cost, productivity loss, and QoL along with their levels of comorbidity. This study identified a main cohort of 122 patients with a hematologic malignancy who responded to Work Productivity and Activity Impairment (WPAI) and EQ-5D-5 L questionnaires. Median patient age was 54.5 years (range 25–71 years), with median Charlson Comorbidity Score (CCI) of 2. Most of the mean total cost (USD 12,836.14; JPY 1,670,624) was attributed to productivity loss (mean USD 8,106.39; JPY 1,055,046) rather than direct medical cost (mean USD 4,729.76; JPY 615,578). Presenteeism (mean USD 5,117.84; JPY 666,086) accounted for a greater proportion of productivity loss than absenteeism (mean USD 2,988.55; JPY 388,960). Deterioration in QoL (-0.045) was observed in comparison to the general population in Japan. The results point to the need for a social security policy to provide appropriate support such as better therapies or access for patients who must receive treatment while still working.